brandoncapital.vcCrawled Nov 10, 2026
Managed by Brandon Capital, Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from Australian and New Zealand member research organisations, providing both capital and expertise to guide the successful development of new therapies.
Brandon Capital creates and manages businesses to ensure investment success beyond traditional funding.
CEPI will provide up to USD4.3 million to Vaxxas to advance its mRNA vaccine patch, which could reduce storage needs and improve distribution.
Novartis acquired Myricx Bio in late August, two years after the company raised a Series A round.
ENA Respiratory received a Notice of Allowance from the USPTO for two patent applications related to respiratory viral infection treatments.
Brandon Capital and Portfolio Companies news stories and press releases.
Alan is a Drug Discovery consultant and Medicinal Chemist with over 30 years of experience at GlaxoSmithKline, where he served as Vice President of Medicinal Chemistry.
David founded Brandon Capital Management and led Peptech’s transition to global operations before joining Pharmacia AB.
Kath was an Investment Manager at Stone Ridge Ventures and co-founded Spark Co-Lab, a medical education provider.
Leighton is an American entrepreneur and investor who previously led Interhealth Partners and Alloy Ventures, and founded Affymax NV’s Pharma Division.
Robert managed science-based product development programs from lab bench to pharmaceutical company integration, most recently as CEO of Elastagen Pty Ltd.
Brandon Capital focuses on responsible investing to build sustainable value and positive impact in its portfolio.
Brandon Capital invests in and supports life science companies from early-stage research through commercialization.
Ways to get in contact with Brandon Capital.
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.